TriLink BioTechnologies

57 articles about TriLink BioTechnologies

• TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

  4/18/2024

  TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility.

• TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada

  2/21/2024

  TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has been granted patents by the China National Intellectual Property Administration and the Canadian Intellectual Property Office.

• TriLink BioTechnologies® Expands Capabilities with Launch of ‘Analytical Sciences Center of Excellence’

  11/2/2023

  TriLink BioTechnologies®, a Maravai LifeSciences company and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence hub.

• TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion

  5/24/2023

  TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers.

• TriLink BioTechnologies Introduces Latest mRNA Capping Technology: CleanCap® M6 analog

  5/9/2023

  TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has launched its newest cap analog, CleanCap® M6.

• TriLink BioTechnologies, Part of Maravai LifeSciences, Expands its mRNA Raw Material Offering with the First GMP-grade Modified Nucleoside-Triphosphate Product

  9/13/2022

  TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Triphosphate, a modified nucleoside-triphosphate essential for mRNA manufacturing.

• TriLink BioTechnologies, part of Maravai LifeSciences, Expands R&D Leadership Team

  7/6/2022

  TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced that Kate Broderick, Ph.D., has joined the Company as Senior Vice President of Research and Development.

• TriLink BioTechnologies® Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea

  10/4/2021

  TriLink BioTechnologies announced that it expects to supply its proprietary CleanCap® mRNA capping technology and the modified nucleoside, uridine triphosphate, to EyeGene, Inc. for production of EyeGene’s mRNA COVID-19 vaccine, EG-COVID, which recently received approval to begin clinical trials from the South Korean Ministry of Food and Drug Safety.

• Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping TechnologyAlliance to expand the range of therapeutic and vaccine applications for the BioXp™ system

  7/21/2021

  Codex DNA, Inc. today announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), for its industry-leading CleanCap® technology.

• Maravai LifeSciences Offers End-to-End mRNA Production with the Launch of TriLink BioTechnologies' Plasmid DNA Manufacturing Services

  3/15/2021

  Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies (“TriLink”) with the launch of its plasmid DNA (pDNA) manufacturing services . TriLink’s new plasmid services empower customers with the ease of an end-to-end messenger RNA (mRNA) solution

• Maravai LifeSciences Expands TriLink BioTechnologies CleanCap® mRNA Capping Capacity and Adds New Plasmid DNA Manufacturing

  8/25/2020

  Second manufacturing expansion within a year will help meet global demand for research, clinical and GMP grade raw materials as well as research and clinical-grade APIs to include mRNA, self-amplifying RNA and plasmid DNA

• TriLink BioTechnologies and Imperial College London Announce Collaboration to Produce saRNA for Covid-19 Vaccine Development

  4/27/2020

  TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA for COVID-19 vaccine development.

• Maravai LifeSciences Hires Two Senior Executives for TriLink BioTechnologies

  2/11/2020

  TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced the addition of two key executives to its leadership team.

• TriLink BioTechnologies Expands IP Portfolio with Two New Patents

  1/7/2020

  TriLink BioTechnologies announced that the United States Patent and Trademark Office has issued two new patents to the company.

• TriLink BioTechnologies Expands Small RNA Sequencing Portfolio With New Primers

  10/14/2019

  Two New Sets of Barcode Convert Primers are Optimized for Ion Torrent* Sequencers

• TriLink BioTechnologies Plays Key Role in Published Study on Single-Cell Sequencing

  11/29/2018

  TriLink BioTechnologies, a Maravai LifeSciences company and a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that the company’s CleanTag® Small RNA Library Prep Kit was the enabling technology in a new study of next-generation sequencing of small RNAs from single cells.

• Maravai LifeSciences Hires Senior Director of Oligonucleotide Process Development for TriLink BioTechnologies

  10/9/2018

  Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced that it has hired Christopher Shaffer as senior director of oligonucleotide process development for TriLink BioTechnologies.

• Maravai LifeSciences Expands Oligonucleotide Business, Leases New Facility for TriLink BioTechnologies

  9/10/2018

  TriLink will consolidate its San Diego facilities into a new 95,000-square-foot space with an option to expand for future growth

• TriLink BioTechnologies Grants ResearchReward For Development Of mRNA Delivery Method

  1/21/2015

• TriLink BioTechnologies Secures Contract For The Synthesis Of Ebola Vaccine

  12/10/2014